Avalo Therapeutics AVTX
NASDAQ AVTX
$19.17 +0.17 (+0.92%)
As of: Sep 4, 2026 · 3:17 PM EDT

Avalo Therapeutics (AVTX) EBITDA Margin Growth (3y) (2019 - 2025)

Analysis

Avalo Therapeutics (AVTX) EBITDA Margin Growth (3y) (2019 - 2025) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA Margin Growth (3y) (Qtr)
1 Vertex Pharmaceuticals 138.51 Bn 130.66 Bn 2.84 Bn -377.00
2 Regeneron Pharmaceuticals 85.24 Bn 77.25 Bn 3.93 Bn -204.00
3 Argenx Se 63.46 Bn 58.28 Bn 1.37 Bn 7,045.00
4 Moderna 57.89 Bn 52.75 Bn 52.00 Mn -1,934.00
5 Revolution Medicines 44.02 Bn 44.02 Bn - -
6 BeOne Medicines 39.95 Bn 34.85 Bn 1.53 Bn 7,261.00
7 Alnylam Pharmaceuticals 35.49 Bn 32.19 Bn 992.69 Mn 9,003.00
8 Royalty Pharma 28.43 Bn 27.59 Bn - -2,649.00
9 Insmed 27.39 Bn 26.22 Bn 358.27 Mn 30,461.00
10 Avalo Therapeutics 836.72 Mn 836.72 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2025 -3.25 Mn
Dec 31, 2024 126,947.00
Sep 30, 2024 -394,558.00
Dec 31, 2023 -24,971.00
Sep 30, 2023 -39,393.00
Jun 30, 2023 -22,894.00
Mar 31, 2023 -71,032.00
Dec 31, 2022 -296.00
Sep 30, 2022 15,739.00
Jun 30, 2022 -96,301.00
Mar 31, 2022 -158,525.00
Dec 31, 2021 -822,696.00
Sep 30, 2021 -62,284.00
Jun 30, 2021 -39,033.00
Mar 31, 2021 -638,137.00
Dec 31, 2020 -86,345.00
Sep 30, 2020 -128,260.00
Jun 30, 2020 24,180.00
Mar 31, 2020 -64,633.00
Dec 31, 2019 -5,876.00